Evaxion Biotech A/S (EVAX)
1.55
-0.14 (-8.28%)
At close: Apr 04, 2025, 3:59 PM
1.50
-3.04%
After-hours: Apr 04, 2025, 04:47 PM EDT
-8.28% (1D)
| Bid | 1.5 |
| Market Cap | 488.59K |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -14 |
| PE Ratio (ttm) | -0.11 |
| Forward PE | -1.56 |
| Analyst | Buy |
| Ask | 1.59 |
| Volume | 65,302 |
| Avg. Volume (20D) | 2,353,224 |
| Open | 1.63 |
| Previous Close | 1.69 |
| Day's Range | 1.50 - 1.65 |
| 52-Week Range | 1.50 - 22.05 |
| Beta | -0.24 |
About EVAX
Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase IIa trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various...
Industry Biotechnology
Sector Healthcare
IPO Date Feb 5, 2021
Employees 49
Stock Exchange NASDAQ
Ticker Symbol EVAX
Website https://www.evaxion-biotech.com
Analyst Forecast
According to 2 analyst ratings, the average rating for EVAX stock is "Buy." The 12-month stock price forecast is $10, which is an increase of 546.41% from the latest price.
Stock ForecastsEarnings Surprise
Evaxion Biotech A/S has released their quartely earnings
on Apr 1, 2025:
Next Earnings Release
Evaxion Biotech A/S is scheduled to release its earnings on May 27, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
-8.56%
Evaxion Biotech shares are trading lower. The stoc...
Unlock content with
Pro Subscription
2 months ago
-27.14%
Evaxion Biotech shares are trading lower after the company announced a public offering of 3,997,361 ADS.
